ライフサイエンスコーパス: solid organ transplant

1 event cytomegalovirus (CMV) infections after solid organ transplant.

2 s of primary cutaneous T-cell lymphoma after solid organ transplant.

3 the short- and long-term clinical outcome of solid organ transplant.

4 cularized cornea behaves like a vascularized solid organ transplant.

5 proved survival for patients with GVHD after solid organ transplant.

6 ective in reducing the incidence of GVD in a solid organ transplant.

7 typically related to immunomodulation during solid-organ transplant.

8 plants and show great promise for women with solid-organ transplant.

9 he most common opportunistic infection after solid-organ transplant.

10 s) were saved to date during the 25 years of solid-organ transplant.

11 the major obstacle for long-term survival of solid organ transplants.

12 nt recipients and may be applicable to other solid organ transplants.

13 plant are similar to those reported in other solid organ transplants.

14 antibodies in acute and chronic rejection of solid organ transplants.

15 on associated with chronic rejection (CR) of solid organ transplants.

16 of NKG2D and its ligands in the rejection of solid organ transplants.

17 BS has rarely been reported in recipients of solid organ transplants.

18 h chronic hepatitis E who were recipients of solid-organ transplants.

19 tion is associated with the deterioration of solid-organ transplants.

20 les for NK cells in reactivity to tissue and solid-organ transplants.

21 ion developed in two groups of recipients of solid-organ transplants.

22 KP infections occurred more frequently among solid organ transplant (31%) and dialysis (17%) patients

23 he records of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients,

24 he registry linkages yielded data on 175,732 solid organ transplants (58.4% for kidney, 21.6% for liv

25 vigorous rejection response elicited against solid organs transplanted across species barriers.

26 Four patients were immunosuppressed after solid organ transplant and all were receiving blood pres

27 f EBV-associated B-cell lymphomas is seen in solid organ transplant and bone marrow transplant recipi

28 tting, we report five new cases of GBS after solid organ transplant and summarize five other cases pr

29 apy for ESBL-producing Enterobacteriaceae in solid organ transplants and MCS device recipients are es

30 d 123 from the literature), 63 had undergone solid-organ transplant and 39 had human immunodeficiency

31 Thirty-five patients with a solid-organ transplant and chronic hepatitis E virus inf

32 or neurologic illness, autoimmune disorders, solid organ transplant, and other significant comorbid c

33 inical trials to treat patients with cancer, solid organ transplants, and autoimmune diseases.

34 to induce rejection compared with most other solid organ transplants, and simultaneous transplantatio

35 g transplantation is among the lowest of all solid-organ transplants, and current diagnostic tests of

36 Recipients of nonrenal solid organ transplants are at risk for acute renal fail

37 Outcomes after solid organ transplants are improving; for adult patient

38 The goals of tolerance in patients with solid organ transplants are to eliminate the lifelong ne

39 omen of reproductive age who have received a solid-organ transplant are at risk for unplanned pregnan

40 Infections following solid-organ transplants are a major cause of morbidity a

41 ded patients with end-stage renal disease or solid organ transplants because very few are uninsured.

42 rejection (SCR) is a known entity in various solid organ transplants but not in intestinal transplant

43 Solid organ transplants contain small numbers of leukocy

44 This may have serious implications in solid-organ transplant deterioration and chronic rejecti

45 w one of the most common bacterial causes of solid-organ transplant donor-derived infection reported

46 this retrospective analysis of UNOS data for solid-organ transplant during a 25-year period (Septembe

47 n 2 million life-years were saved to date by solid-organ transplants during a 25-year study period.

48 umoral rejection is the most common cause of solid organ transplant failure.

49 From 1999 to 2010, we performed solid organ transplants for 1331 recipients at our insti

50 The charts of all patients receiving a solid organ transplant from 1990-2008 evaluated in the d

51 n the United States who received their first solid organ transplant from 1994 to 2005 (N = 210 763) u

52 tions have been shown to dramatically affect solid organ transplant graft survival in both human and

53 measurements as infection risk markers after solid organ transplant has not been fully investigated.

54 noninvasive methods to diagnose rejection in solid-organ transplants has been rejuvenated by recent o

55 sepsis; however, experience in recipients of solid-organ transplants has not been addressed.

56 inimization and avoidance protocols for post-solid organ transplant have been developed.

57 Long-term survivors of solid organ transplants have an 9-fold increased risk of

58 Immunosuppressed patients with solid organ transplants have an increased risk for nonme

59 Between 2002 and 2004, 8,198 solid organ transplants have been performed in Italy, 10

60 partners, bridges research in the fields of solid organ transplant, hematopoietic cell transplant, a

61 lant failure or rejection (HR 3.2), previous solid organ transplant (HR 1.7), and several comorbiditi

62 duction and maintenance immunosuppression in solid organ transplants, including whole pancreas and ki

63 city and positive predictive value for other solid-organ transplants increased to 92.9% and 62.5%, re

64 ctious disease consultation in recipients of solid organ transplant is associated with increased LOS

65 Ab-mediated rejection (AMR) of solid organ transplants is characterized by intragraft m

66 ere sepsis in immunosuppressed recipients of solid-organ transplants is associated with a high mortal

67 nly associated with poor outcome after other solid organ transplants, it has not been studied in deta

68 thritis (n = 97), hematopoietic stem-cell or solid organ transplant (n = 26), or a general cohort of

69 deficiency virus coinfection, renal disease, solid-organ transplant, neuropyschiatric disease, autoim

70 hing is not considered important in nonrenal solid organ transplants (NRSOT).

71 erval, 1.1-14, P = 0.04), while preadmission solid organ transplant (odds ratio, 0.37; 95% confidence

72 Receiving a solid organ transplant owing to late-stage organ failure

73 sed by Nocardia thailandica in a 66-year-old solid organ transplant patient from Connecticut, which w

74 n a stereotactic core biopsy specimen from a solid organ transplant patient with EBV(+) PCNSL.

75 We reviewed 1593 solid organ transplant patients and reported the frequen

76 unoglobulin was identified in only 3% of all solid organ transplant patients pretransplant (n=34).

77 ill, oncologic or stem cell transplant, and solid organ transplant patients showed a relationship be

78 4 expression by cryptococcal strains from 24 solid organ transplant patients was associated with diss

79 One hundred and fifty-three solid organ transplant patients were enrolled, including

80 One hundred seven adult solid organ transplant patients were identified at the M

81 We studied six cases of CMV replication in solid organ transplant patients whose genotypic testing

82 Solid organ transplant patients with first episode of CM

83 a Southwest Oncology Group clinical trial of solid organ transplant patients with PTLD.

84 (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal da

85 In solid organ transplant patients, global suppression of i

86 with medication, could predict adherence in solid organ transplant patients.

87 skin malignancies and emotional distress in solid organ transplant patients.

88 ble peptide-based vaccine to prevent PTLD in solid organ transplant patients.

89 emerged as a cause of persistent diarrhea in solid organ transplant patients.

90 romised individuals, such as bone marrow and solid organ transplant patients.

91 ed all cryptosporidiosis cases identified in solid organ transplanted patients between 2006 and 2010

92 Solid organ transplanted patients have a three- to fourf

93 trated efficacy in preventing CMV disease in solid-organ transplant patients as well as congenital di

94 ional markers aimed at identifying long-term solid-organ transplant patients at high risk of developi

95 We assessed kidney function and histology in solid-organ transplant patients during HEV infection.

96 24% of Cryptococcus neoformans isolates from solid-organ transplant patients exhibited altered sensit

97 strategy to prevent infection and disease in solid-organ transplant patients has not been evaluated b

98 been used to treat chronic HEV infection in solid-organ transplant patients with some success.

99 th significant morbidity and mortality among solid-organ transplant patients, but approaches to diagn

100 cies in ORF1 and the outcome of infection in solid-organ transplant patients.

101 ating chronic hepatitis E virus infection in solid-organ transplant patients.

102 g transplantation lags behind that for other solid organ transplants, primarily because of allograft

103 d trials and experience from other pediatric solid organ transplant recipient populations will contin

104 topathologic abnormalities are common in the solid organ transplant recipient with diarrhea, the find

105 six cases of PTLD were identified with 1392 solid-organ transplant recipient controls.

106 even patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis

107 life-years were saved (observed to date) per solid-organ transplant recipient.

108 conducted a retrospective cohort study of US solid organ transplant recipients (1997-2007).

109 We reported 47 solid organ transplant recipients (41 kidneys) with cryp

110 dverse outcomes are cytomegalovirus (CMV) in solid organ transplant recipients (causing rejection), C

111 A meta-analysis of 504 solid organ transplant recipients (heart, kidney, kidney

112 phylaxis of cytomegalovirus (CMV) disease in solid organ transplant recipients (n = 240/372).

113 The increased incidence of skin cancers in solid organ transplant recipients (OTR) has been well es

114 reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has e

115 ntibody response to the 2009-H1N1 vaccine in solid organ transplant recipients (SOTR) and its clinica

116 s on the use of generic immunosuppression in solid organ transplant recipients (SOTR) based on a revi

117 De novo solid organ transplant recipients (SOTR) have a steep le

118 Solid organ transplant recipients (SOTR) with a pretrans

119 enza vaccine effectiveness is not optimal in solid organ transplant recipients (SOTR).

120 or contributor to morbidity and mortality in solid organ transplant recipients (SOTRs).

121 view available data on coccidioidomycosis in solid organ transplant recipients and candidates seeking

122 e multiple risk factors for CNS processes in solid organ transplant recipients and establishes a time

123 Diabetes is prevalent among solid organ transplant recipients and is universal among

124 excess risk are similar to those observed in solid organ transplant recipients and patients with auto

125 tion of pretransplantation HLA antibodies in solid organ transplant recipients and, in particular, th

126 EBV-seronegative solid organ transplant recipients are at high risk of EB

127 Solid organ transplant recipients are at increased risk

128 as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited.

129 Solid organ transplant recipients commonly are infected

130 n addition, a significant number of nonrenal solid organ transplant recipients develop chronic kidney

131 Another cluster of solid organ transplant recipients developed encephalitis

132 Solid organ transplant recipients enrolled in an interna

133 ssociated cluster of febrile illness among 3 solid organ transplant recipients from a common donor.

134 Solid organ transplant recipients from HHV-8 endemic reg

135 TICIPANTS: Cohort study using linked data on solid organ transplant recipients from the US Scientific

136 Solid organ transplant recipients have a 60-250-fold inc

137 Solid organ transplant recipients have a high incidence

138 Solid organ transplant recipients have elevated cancer r

139 Solid organ transplant recipients have heightened risk f

140 Solid organ transplant recipients have increased risk fo

141 nervous system (CNS) cryptococcal lesions in solid organ transplant recipients have not been fully de

142 ntified a Swedish population-based cohort of solid organ transplant recipients in the National Patien

143 ecipients, which contains information on all solid organ transplant recipients in the United States,

144 Solid organ transplant recipients receive immunosuppress

145 Thus, CMV D+/R- solid organ transplant recipients receiving 3 months of

146 eatment outcomes during CMV infection in 291 solid organ transplant recipients receiving valganciclov

147 ction in almost all reported cases of GBS in solid organ transplant recipients suggest that CMV may h

148 ng Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management o

149 Treatment failure or relapse is common in solid organ transplant recipients treated for cytomegalo

150 cancer was assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox

151 Solid organ transplant recipients were identified within

152 eventing CMV and associated complications in solid organ transplant recipients were selected.

153 Non-lung solid organ transplant recipients who developed NSCLC ha

154 In solid organ transplant recipients who presented at our i

155 ates that elevated osteoprotegerin levels in solid organ transplant recipients with CMV infection may

156 Patients were derived form a cohort of 122 solid organ transplant recipients with cryptococcosis in

157 pecific diagnosis and changing management in solid organ transplant recipients with diarrhea.

158 75] days before ICU admission), 4 (10%) were solid organ transplant recipients, and 10 (27%) were inf

159 view the current status of CMV resistance in solid organ transplant recipients, and provide diagnosti

160 In this study of 649 solid organ transplant recipients, followed prospectivel

161 most common opportunistic viral infection in solid organ transplant recipients, is associated with su

162 erebral vasculature that occurs in 0.5-5% of solid organ transplant recipients, most commonly associa

163 Among other solid organ transplant recipients, no significant improv

164 ctivation can cause significant morbidity in solid organ transplant recipients, particularly BK virus

165 hough diarrhea is a frequent complaint among solid organ transplant recipients, the contribution of i

166 tors for invasive mold infections among 1101 solid organ transplant recipients, thereby strengthening

167 Solid organ transplant recipients, who are medically imm

168 er phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20(+) PTLD unr

169 D) is an increasingly important diagnosis in solid organ transplant recipients, with rising incidence

170 stemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients.

171 ting for chronic hepatitis in some pediatric solid organ transplant recipients.

172 endations are likely to be relevant to other solid organ transplant recipients.

173 ory affects posttransplantation mortality in solid organ transplant recipients.

174 to these viruses are reported only in 1% of solid organ transplant recipients.

175 t of early- and late-onset PTLD in pediatric solid organ transplant recipients.

176 for improving the cardiovascular outcomes of solid organ transplant recipients.

177 on growth and safety parameters in pediatric solid organ transplant recipients.

178 new causative agent of chronic hepatitis in solid organ transplant recipients.

179 may have a role in renal dysfunction in some solid organ transplant recipients.

180 ation with opportunistic infections (OIs) in solid organ transplant recipients.

181 treatment failure during anti-CMV therapy in solid organ transplant recipients.

182 nt medication is a significant problem among solid organ transplant recipients.

183 ify risk factors of Hodgkin lymphoma (HL) in solid organ transplant recipients.

184 t cause of morbidity, mortality, and cost in solid organ transplant recipients.

185 l-based adjunct immunosuppressive therapy in solid organ transplant recipients.

186 Diarrhea is common in solid organ transplant recipients.

187 r, have the highest rate of infections among solid organ transplant recipients.

188 spective multicenter phase II study of adult solid organ transplant recipients.

189 ematopoietic stem-cell transplant (HSCT) and solid organ transplant recipients.

190 eneficial in preventing CMV organ disease in solid organ transplant recipients.

191 ccurs in a small but significant minority of solid organ transplant recipients.

192 -threatening complication in bone marrow and solid organ transplant recipients.

193 can occur in the native kidneys of nonrenal solid organ transplant recipients.

194 urological complications occur frequently in solid organ transplant recipients.

195 ell recognized but uncommon complications in solid organ transplant recipients.

196 nd a leading cause of cancer mortality among solid organ transplant recipients.

197 iclovir for cytomegalovirus (CMV) disease in solid organ transplant recipients.

198 a major cause of graft loss and mortality in solid organ transplant recipients.

199 ing the incidence of rejection in HIV-to-HIV solid organ transplant recipients.

200 ysis over an 18-month period of hospitalized solid organ transplant recipients.

201 y of cases of antibody-mediated rejection in solid organ transplant recipients.

202 ients receiving immunosuppressing drugs, and solid organ transplant recipients.

203 infectious disease-related complications in solid organ transplant recipients.

204 ant strains was examined in a large group of solid organ transplant recipients; drug-resistant CMV wa

205 The treatments and outcomes of three solid-organ transplant recipients (liver, kidney, and ki

206 umatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8%

207 Solid-organ transplant recipients (OTRs) are at an incre

208 Although solid-organ transplant recipients (SOTR) have an increas

209 Immunosuppression (IS), such as in solid-organ transplant recipients (SOTRs) and patients w

210 Solid-organ transplant recipients (SOTRs) are at greater

211 0 fresh CMV DNA-positive plasma samples from solid-organ transplant recipients (SOTRs) were tested.

212 oad after preemptive therapy with VGCV in 22 solid-organ transplant recipients (T1/2=2.16 days), comp

213 Ad infections are a serious problem for solid-organ transplant recipients and AIDS patients as w

214 itution of antifungal therapy among non-lung solid-organ transplant recipients and helped to rule out

215 ted to occur during transitions of care, and solid-organ transplant recipients are at an increased ri

216 Solid-organ transplant recipients are at increased risk

217 Solid-organ transplant recipients are at risk for develo

218 A total of 840 solid-organ transplant recipients at risk for CMV infect

219 isted of a retrospective chart review of all solid-organ transplant recipients from 1990 to 2000.

220 he circulations of 16 asymptomatic pediatric solid-organ transplant recipients from Children's Hospit

221 ta of pandemic influenza A H1N1 infection in solid-organ transplant recipients have been described, b

222 tein-Barr Virus (EBV) infection in pediatric solid-organ transplant recipients often leads to an asym

223 Prednisolone metabolism is slower in solid-organ transplant recipients than in healthy subjec

224 e aspects that are more specific to nonrenal solid-organ transplant recipients with a focus on liver,

225 Moreover, in solid-organ transplant recipients with active CMV infect

226 We describe four solid-organ transplant recipients with donor-derived Wes

227 the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV vir

228 compares the present case to those of other solid-organ transplant recipients with the same infectio

229 use serious complications in bone-marrow and solid-organ transplant recipients, and current therapies

230 inhibitors, patients receiving hemodialysis, solid-organ transplant recipients, and patients with can

231 fluence susceptibility to CMV replication in solid-organ transplant recipients, particularly in patie

232 onmelanoma skin cancer is well recognized in solid-organ transplant recipients, the risk of skin canc

233 CMV) disease remains an important problem in solid-organ transplant recipients, with the greatest ris

234 immunocompromised individuals, especially in solid-organ transplant recipients.

235 invasive pulmonary aspergillosis (IPA) among solid-organ transplant recipients.

236 thy (TMA) has been described in up to 14% of solid-organ transplant recipients.

237 sary surgical or diagnostic interventions in solid-organ transplant recipients.

238 cluding the iatrogenic form that presents in solid-organ transplant recipients.

239 ng a cohort consisting of children and adult solid-organ transplant recipients.

240 e in accordance with reports regarding other solid-organ transplant recipients.

241 implementation, which was not seen in other solid-organ transplant recipients.

242 idence of cytomegalovirus (CMV) infection in solid-organ transplant recipients.

243 ital charges among lung transplant and other solid-organ transplant recipients.

244 Twenty-four solid-organ-transplant recipients with chronic hepatitis

245 Through linkage of the US solid organ transplant registry with 15 state/regional c

246 er, the role of TNF-R1-mediated signaling in solid organ transplant rejection has not been defined.

247 rtant non-heme Fe-S cluster protein in acute solid organ transplant rejection.

248 iew is to discuss the current and historical solid organ transplant-related disruptions in the supply

249 nd long-term graft survival (like with other solid organ transplants) remains a challenge, the future

250 Records of solid organ transplant (SOT) and hematopoietic cell tran

251 cause of morbidity and mortality among both solid organ transplant (SOT) and hematopoietic stem cell

252 cal and molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in no

253 Two groups were identified: the solid organ transplant (SOT) group (n = 15; 12 ITX and 3

254 s a potentially fatal disorder arising after solid organ transplant (SOT) or hematopoietic stem cell

255 In the solid organ transplant (SOT) population, manifestations

256 Solid organ transplant (SOT) recipients are at elevated

257 Solid organ transplant (SOT) recipients are at risk for

258 Solid organ transplant (SOT) recipients are at risk of n

259 Although solid organ transplant (SOT) recipients are particularly

260 ic T lymphocytes (CTLs) for the treatment of solid organ transplant (SOT) recipients at high risk for

261 ecific cytotoxic T lymphocytes (EBV-CTLs) to solid organ transplant (SOT) recipients has been shown s

262 ence of invasive fungal infections (IFIs) in solid organ transplant (SOT) recipients has increased du

263 Approximately 3%-10% of solid organ transplant (SOT) recipients in CRE-endemic a

264 e of immune reconstitution syndrome (IRS) in solid organ transplant (SOT) recipients with cryptococco

265 We sought to determine whether a subset of solid organ transplant (SOT) recipients with high likeli

266 ical characteristics, risks, and outcomes in solid organ transplant (SOT) recipients with zygomycosis

267 significant manifestation of zygomycosis in solid organ transplant (SOT) recipients.

268 CMV) is an emerging and important problem in solid organ transplant (SOT) recipients.

269 liferative disorders (PTLD) affect 2%-27% of solid organ transplant (SOT) recipients.

270 ons have the potential to affect outcomes in solid organ transplant (SOT) recipients.

271 ug-resistant (XDR) Pseudomonas aeruginosa in solid organ transplant (SOT) recipients.

272 utcomes associated with histoplasmosis after solid organ transplant (SOT), we report a large series o

273 med a multicenter, International analysis of solid organ transplant (SOT)-related primary central ner

274 erculosis infection (LTBI) is recommended in solid organ transplant (SOT).

275 lity after hematopoietic stem cell (HSCT) or solid organ transplant (SOT).

276 n, affecting 0.04% to 3.5% of patients after solid organ transplant (SOT).

277 Sepsis is a serious complication of solid organ transplant (SOT).

278 gained over the years shows that, similar to solid organ transplants (SOT), human VCA can also develo

279 V) is an important pathogen in recipients of solid organ transplants (SOT).

280 reatment of latent tuberculosis infection in solid-organ transplant (SOT) candidates.

281 finger-stick DBS and plasma samples from 35 solid-organ transplant (SOT) patients.

282 Solid-organ transplant (SOT) recipients are considered t

283 econstitution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known.

284 Immunological parameters that distinguish solid-organ transplant (SOT) recipients at risk for life

285 Cytomegalovirus (CMV) D+/R- solid-organ transplant (SOT) recipients carry increased

286 ding bacteremia caused by these organisms in solid-organ transplant (SOT) recipients is lacking.

287 (IMI) among hematopoietic stem cell but not solid-organ transplant (SOT) recipients.

288 derlying illnesses were as follows: 13 (29%) solid-organ transplant (SOT), 11 (24%) BMT, and 7 (13%)

289 Co-management with a solid organ transplant specialist is helpful for the mon

290 related outcomes across a range of different solid-organ transplant studies.

291 tudy was to assess the periodontal status of solid-organ transplant subjects compared to systemically

292 jection, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart

293 GVHD is a rare complication of solid organ transplants that usually presents early afte

294 inking hematopoietic chimerism induction and solid organ transplant tolerance, the mechanistic requir

295 how preexisting autoreactive T cells affect solid-organ transplants under these conditions is unknow

296 ividuals with inflammatory bowel diseases or solid-organ transplants, virome dynamics in allogeneic h

297 A panel of experts on CMV and solid organ transplant was convened by The Infectious Di

298 ransplants and reduced long-term survival of solid organ transplants, we hypothesized that convention

299 ent and Transplantation Network data, 28 051 solid organ transplants were performed in 2012.

300 Animal organs could satisfy the demand for solid organ transplants, which currently exceeds the lim